Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an average annual return of 12.68%. Currently, Vertex Pharmaceuticals has a market capitalization of $106.01 billion.
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily loss of 0.
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.
Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports. A number of other equities research analysts have also commented on VRTX.
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
The FDA is scheduled to make an approval decision for suzetrigine in treating acute pain by Jan. 30, 2025. This non-opioid pain drug targets a multibillion-dollar market. Vertex also has multiple other catalysts on the way in 2025 and over the next few years.
news.stocktradersdaily23h
How the (VRTX) price action is used to our Advantage
Part of that involves looking at the #fundamentals, but half of the disclosure comes from looking at price action.
Vertex Pharmaceuticals: Strong Pipeline and Strategic Growth Propel ‘Buy’ Rating
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Vertex Grapples With Bearish Chart As Death Cross Emerges
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.
Yahoo Finance9d
INCY vs. VRTX: Which Stock Is the Better Value Option?
VRTX currently has a PEG ratio of 1.85. Another notable valuation metric for INCY is its P/B ratio of 4.44. The P/B ratio pits a stock's market value against its book value, which is defined as ...
The Globe and Mail5d
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
Before you risk a nickel on this volatile biotech stock, you should know that sales of Casgevy haven't gotten off the ground yet. The company's collaboration partner, Vertex Pharmaceuticals(NASDAQ: ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX)
Analysts fell to the sidelines weighing in on Exelixis (EXEL – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report) with ...